Lotus Eye Hospital [LOTUSEYE] vs Dr. Agarwal's Eye [DRAGARWQ] Detailed Stock Comparison

Lotus Eye Hospital and Institute Ltd.

NSE
Loading...

Dr. Agarwal's Eye Hospital Ltd.

BSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Lotus Eye Hospital and Institute Ltd. wins in 6 metrics, Dr. Agarwal's Eye Hospital Ltd. wins in 11 metrics, with 0 ties. Dr. Agarwal's Eye Hospital Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Lotus Eye Hospital and Institute Ltd. Dr. Agarwal's Eye Hospital Ltd. Better
P/E Ratio (TTM) 371.78 34.01 Dr. Agarwal's Eye Hospital Ltd.
Price-to-Book Ratio 3.79 7.52 Lotus Eye Hospital and Institute Ltd.
Debt-to-Equity Ratio 7.92 106.45 Lotus Eye Hospital and Institute Ltd.
PEG Ratio 20.45 1.81 Dr. Agarwal's Eye Hospital Ltd.
EV/EBITDA 102.16 20.64 Dr. Agarwal's Eye Hospital Ltd.
Profit Margin (TTM) 1.26% 15.50% Dr. Agarwal's Eye Hospital Ltd.
Operating Margin (TTM) -2.40% 19.54% Dr. Agarwal's Eye Hospital Ltd.
EBITDA Margin (TTM) N/A 19.54% N/A
Return on Equity 1.23% 26.07% Dr. Agarwal's Eye Hospital Ltd.
Return on Assets (TTM) 1.06% 8.91% Dr. Agarwal's Eye Hospital Ltd.
Free Cash Flow (TTM) $-21.28M $-83.80M Lotus Eye Hospital and Institute Ltd.
Dividend Yield N/A 0.11% N/A
1-Year Return 51.00% 14.52% Lotus Eye Hospital and Institute Ltd.
Price-to-Sales Ratio (TTM) 4.79 5.39 Lotus Eye Hospital and Institute Ltd.
Enterprise Value $2.23B $26.69B Dr. Agarwal's Eye Hospital Ltd.
EV/Revenue Ratio 4.31 5.92 Lotus Eye Hospital and Institute Ltd.
Gross Profit Margin (TTM) N/A 78.09% N/A
Revenue per Share (TTM) $25 $952 Dr. Agarwal's Eye Hospital Ltd.
Earnings per Share (Diluted) $0.32 $147.68 Dr. Agarwal's Eye Hospital Ltd.
Beta (Stock Volatility) 0.57 -0.57 Dr. Agarwal's Eye Hospital Ltd.

Lotus Eye Hospital and Institute Ltd. vs Dr. Agarwal's Eye Hospital Ltd. Stock Performance Analysis

Loading Price Chart...

LOTUSEYE
DRAGARWQ

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Lotus Eye Hospital and Institute Ltd.1.54%-0.96%-6.91%0.66%1.59%-10.03%
Dr. Agarwal's Eye Hospital Ltd.2.18%-1.97%-1.17%9.73%-11.83%-5.80%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Lotus Eye Hospital and Institute Ltd.51.00%48.22%137.31%600.45%887.00%204.54%
Dr. Agarwal's Eye Hospital Ltd.14.52%234.64%1,085.59%2,491.74%5,250.78%17,139.34%

Performance & Financial Health Analysis: Lotus Eye Hospital and Institute Ltd. vs Dr. Agarwal's Eye Hospital Ltd.

MetricLOTUSEYEDRAGARWQ
Market Information
Market Cap i₹2.63B₹24.28B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i18,1281,256
90 Day Avg. Volume i13,5951,378
Last Close₹110.04₹5,127.50
52 Week Range₹67.72 - ₹147.00₹4,142.00 - ₹6,392.00
% from 52W High-25.14%-19.78%
All-Time High₹147.00 (Jan 30, 2026)₹7,300.00 (Dec 30, 2024)
% from All-Time High-25.14%-29.76%
Growth Metrics
Quarterly Revenue Growth0.11%0.22%
Quarterly Earnings GrowthN/A0.66%
Financial Health
Profit Margin (TTM) i0.01%0.16%
Operating Margin (TTM) i-0.02%0.20%
Return on Equity (TTM) i0.01%0.26%
Debt to Equity (MRQ) i7.92106.45
Cash & Liquidity
Book Value per Share (MRQ)₹31.41₹668.22
Cash per Share (MRQ)₹1.62₹191.98
Operating Cash Flow (TTM) i₹5.77M₹738.70M
Levered Free Cash Flow (TTM) i₹7.39M₹546.50M
Dividends
Last 12-Month Dividend Yield iN/A0.11%
Last 12-Month Dividend i₹0.00₹5.00

Valuation & Enterprise Metrics Analysis: Lotus Eye Hospital and Institute Ltd. vs Dr. Agarwal's Eye Hospital Ltd.

MetricLOTUSEYE (Apr 24, 2026)DRAGARWQ (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i371.7834.01
Forward P/E iN/A516.77
PEG Ratio i20.451.81
Price to Sales (TTM) i4.795.39
Price to Book (MRQ) i3.797.52
Market Capitalization
Market Capitalization i₹2.63B₹24.28B
Enterprise Value i₹2.23B₹26.69B
Enterprise Value Metrics
Enterprise to Revenue i4.315.92
Enterprise to EBITDA i102.1620.64
Risk & Other Metrics
Beta i0.57-0.57
Book Value per Share (MRQ) i₹31.41₹668.22

Financial Statements Comparison: Lotus Eye Hospital and Institute Ltd. vs Dr. Agarwal's Eye Hospital Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricLOTUSEYE (2025)DRAGARWQ (2025)
Revenue/Sales i486.03M3.94B
Cost of Goods Sold i259.50M896.20M
COGS % of Revenue i53.4%22.8%
Gross Profit i226.53M3.04B
Gross Margin i46.6%77.2%
Research & Development iN/AN/A
Operating Income (EBIT) i5.52M813.30M
Operating Margin i1.1%20.6%
EBITDA i47.35M1.22B
EBITDA Margin i9.7%31.1%
Pre-Tax Income i13.83M707.00M
Pre-Tax Income % of Revenue i2.8%17.9%
Income Tax i6.43M160.50M
Income Tax % of Revenue i1.3%4.1%
Net Income (Profit) i7.39M546.50M
Profit Margin i1.5%13.9%

Balance Sheet & Liquidity Metrics

MetricLOTUSEYE (2025)DRAGARWQ (2025)
Cash & Equivalents i20.11M111.60M
Total Current Assets i115.70M559.40M
Total Current Assets % of Revenue i23.8%14.2%
Total Current Liabilities i74.25M869.80M
Total Current Liabilities % of Revenue i15.3%22.1%
Long-Term Debt i20.27M3.06B
Long-Term Debt % of Revenue i4.2%77.6%
Total Shareholders Equity i600.00M2.10B
Retained Earnings i143.09M1.99B
Retained Earnings % of Revenue i29.4%50.4%
Property, Plant & Equipment i442.83M1.37B

Cash Flow Statement Comparison

MetricLOTUSEYE (2025)DRAGARWQ (2025)
Operating Cash Flow i5.77M738.70M
Operating Cash Flow % of Revenue i1.2%18.8%
Capital Expenditures i-47.90M4.10M
Free Cash Flow i-21.28M-83.80M
FCF Margin i-4.4%-2.1%
Debt Repayment iN/A-111.30M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricLOTUSEYEDRAGARWQ
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i20.80M4.83M
Float Shares i4.56M1.08M
% Held by Insiders i71.94%77.59%
% Held by Institutions i0.00%3.57%
% Held by Public i28.06%18.84%

Dividend Analysis & Yield Comparison: Lotus Eye Hospital and Institute Ltd. vs Dr. Agarwal's Eye Hospital Ltd.

MetricLOTUSEYEDRAGARWQ
Last 12-Month Dividend i₹0.00₹5.00
Last 12-Month Dividend Yield iN/A0.11%
3-Year Avg Annual Dividend i₹0.33₹4.50
3-Year Avg Dividend Yield i0.66%0.12%
3-Year Total Dividends i₹1.00₹13.50
Ex-Dividend DateSep 18, 2023Nov 08, 2024